

Broadening Gene Discovery for Alzheimer's Disease

Incorporating Cerebrovascular Risk Factors and Examining Multi-Omics Profiles to Unravel Mechanisms and Causal Pathways

Zhengwei Song, Zuoqiao Cui, Annie J. Lee*

^{1,2}Columbia University Mailman School of Public Health, ³Columbia University Department of Neurology

BACKGROUND

- Cardiovascular risk factors (CVRFs) increase the risk of cerebrovascular disease and clinical Alzheimer's Disease (AD), and over 30% of the patients with AD coincident cerebrovascular pathology.
- We previously found that FMNL2 interacts with CVRFs ($p=6.6 \times 10^{-7}$) by altering the normal astroglial-vascular mechanisms that underly amyloid clearance¹. Identify additional genes that contribute to the interaction between CVRFs and AD will provide greater insight into the genetic factors associated with AD, which can help understand the **multifactorial etiology of AD**.




Figure 1. FMNL2 interacts with CVRFs altering mechanisms that underly amyloid clearance¹

OBJECTIVES & DATA

Objectives: Gene Discovery with Mechanisms and causal pathways

- Using **multi-omics** data can provide a comprehensive perspective on disease mechanisms, which helps to understand the complexity of AD at the molecular level




Figure 2. Studying the relationship between CVRFs, cerebro-vascular pathology, AD and its pathology

Data Overview

- Frontal Cortex Data from Religious Orders Study/Memory and Aging Project (ROSMAP)², with eight multi-ethnic study batches
 - Genotype:** 11,480,632 SNPs, with 530 AD patients, 503 controls, and 861 others
 - Proteomics:** 7,737 proteins, with 184 AD patients, 134 controls, and 82 others
 - Bulk RNA sequencing:** 18,629 genes, with 688 AD patients and 404 controls
 - Phenotype:** 19,028 variables, with 688 AD patients and 404 controls
- Quality Control
 - Omics count data Normalization by TMM
 - Regressed each omics feature out by age, sex and 11 processing factors, and used residual as the final omics value
 - Technical factors adjustment by extracting correlation matrix between 20 Principal Components (PCs) from the previous residuals and technical variables including study batch. In addition, a forward selection approach using the voom/limma pipeline is to verify technical factors.

METHODS

- CVRF score** was created from the first principal component of self-reported history of hypertension, diabetes, and heart disease, and measured BMI
- Genome-wide gene-CVRF score (GxE)** interaction analysis for AD
- Gene-based interaction by the **adaptive gene-environment interaction (aGE) test**, results were summarized using a meta-analysis
 - aGE Model: Phenotype \sim SNP + GxE + SNP*GxE + Age + Sex, adjusted by top 3 genotype PCs
- Trait Analysis:** Tested the association between pathological AD, amyloid- β , tangles deposition (tau), and 45 brain infarction regions with gene and protein expression from the frontal cortex. Age and sex were adjusted in all models.
 - AD \sim Omics (Transcript/Protein)
 - Omics (Transcript/Protein) \sim AD Pathology (amyloid/tau) in AD patients
 - Infarction Region \sim Omics (Transcript/Protein) *AD Pathology (amyloid/tau)
 - Infarction Region \sim Omics (Transcript/Protein) in all sample and AD patients
 - AD \sim Infarction Region * Omics (Transcript/Protein)
- Causal Mediation Analysis**
 - Omics (Transcript/protein) \rightarrow AD Pathology (amyloid/tau) \rightarrow AD
 - AD Pathology (amyloid/tau) \rightarrow Omics (Transcript/Protein) \rightarrow Infarction Region

RESULTS

- The previous **interaction of CVRF score with FMNL2 on AD** ($p=3.64 \times 10^{-7}$) was **strengthened** and **additional genes were identified including BRINP1** ($p=2.45 \times 10^{-6}$), **CFAP99** ($p=3.30 \times 10^{-6}$), and **PRG3** ($p=3.71 \times 10^{-6}$).
- FMNL2 encodes a formin-related protein important in regulating actin and microtubules.
- FMNL2 and BRINP1** gene expressions were **higher in the brains of patients with brain infarcts** ($p = 0.025$ and $p = 0.006$).
- protein expression was associated with pathological AD ($p=0.0002$) and was BRINP1 higher in the brains of patients with brain infarcts ($p = 0.022$).
- 51 candidate genes detected** from aGE test ($FDR < 0.05$); **Amyloid- β fully mediates between BRINP1, TPR, PTPRF and AD**, respectively ($FDR < 0.05$); **Tangles Deposition fully mediates TPR, PTPRF and AD**, respectively ($FDR < 0.05$), and **partially mediates between TPR, PTPRF and AD**, respectively ($FDR < 0.05$).
- BRINP1, SCIN, PTPRF fully mediates between Amyloid- β & Tangles Deposition and some of 7 Infarction Regions.** ($FDR < 0.05$)




Figure 3. Result for the relationship between CVRFs, cerebro-vascular pathology, AD and its pathology

CONCLUSIONS

- The **four novel genes (FMNL2, BRINP1, CFAP99, PRG3)** are likely to be involved in the complex **interaction between Alzheimer's disease pathology** (amyloid and phosphorylated tau deposition) and **cerebrovascular pathology** at the glia-vascular interface during AD progression. Understanding how these genes interfere with the mechanisms in brain will be essential.
- Pathway Mediation by Amyloid- β :** The relationship between three novel genes (BRINP1, TPR, PTPRF) and AD is fully explained by the role of Amyloid- β .
- Pathway Mediation by Tangles Deposition:** The effect of two novel genes (TPR, PTPRF) on AD is entirely channeled through Tangles Deposition. Furthermore, it partially mediates between TPR, PTPRF, and AD, suggesting that Tangles Deposition is a significant but not the sole pathway of influence.
- Gene & Protein Mediation Impacting Infarction Regions:** The genes BRINP1, SCIN, and PTPRF are complete mediators between Amyloid- β & Tangles Deposition and some of the 7 Infarction Regions identified. This indicates a direct pathway where these genes mediate the effects of Amyloid- β and Tangles Deposition on specific brain regions affected by infarction.

ACKNOWLEDGEMENT

- This research is supported by National Institutes of Health grants, Taub Institute Schaefer Research Scholars Award. We thank Dr. Annie J. Lee for her leadership and mentorship to this project.

REFERENCES

- Lee, A. J., Raghavan, N. S., Bhattarai, P, et al. (2022). FMNL2 regulates gliovascular interactions and is associated with vascular risk factors and cerebrovascular pathology in Alzheimer's disease. *Acta neuropathologica*, 144(1), 59–79. <https://doi.org/10.1007/s00401-022-02431-6>
- Bennett, D. A., Buchman, A. S., Boyle, P. A., Barnes, L. L., Wilson, R. S., & Schneider, J. A. (2018). Religious Orders Study and Rush Memory and Aging Project. *Journal of Alzheimer's disease : JAD*, 64(s1), S161–S189. <https://doi.org/10.3233/JAD-179939>